Related Experiment Video
Updated: May 5, 2026
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Novel boron-modified aza-BODIPY photosensitizers for low-dose light-dependent anti-cancer photodynamic therapy
Mei Hu1, Xiaochun Dong1, Weili Zhao1
1Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Abstract:
The aggregation-induced decrease in photosensitization activity is one of the major challenges limiting the clinical application of photosensitizers (PSs). Thus, developing highly efficient PSs for anti-cancer photodynamic therapy (PDT) remains an urgent need. To address this challenge, we designed and synthesized a novel family of efficient aza-BODIPY PSs by inhibiting aggregation with a boron-modified strategy. These novel aza-BODIPY PSs demonstrated significantly enhanced in vitro photodynamic efficacy. Of particular note was derivative A1, which emerged as a highly promising NIR PS with high singlet oxygen yield (rel.rate = 1.79) that obviously superior to the reported compound BDP 4 (rel.rate = 1.23) in PBS. Additionally, A1 showed exceptional cytotoxicity against various cells (IC50 > 4.5 nM) at a low light dose of 21.6 J/cm2. In vivo anti-tumor experiments showed that significant tumor growth suppression following intravenous administration of A1 (2 mg/kg) and subsequent irradiation (21.6 J/cm2, λ = 660 nm), outperforming well-known PSs such as ADPM06 and Ce6. Both in vitro and in vivo studies revealed that A1 exhibited an excellent PDT effect at remarkable low drug and light doses.
Insights
Researchers developed new boron-modified aza-BODIPY photosensitizers (PSs) to overcome aggregation issues in anti-cancer photodynamic therapy (PDT). Derivative A1 shows potent anti-tumor activity with low drug and light doses, offering a promising PDT strategy.
Area of Science:
- Materials Science
- Chemistry
- Biomedical Engineering
Background:
- Aggregation-induced decrease in photosensitization activity limits clinical use of photosensitizers (PSs).
- Developing efficient PSs for anti-cancer photodynamic therapy (PDT) is crucial.
Purpose of the Study:
- To design and synthesize novel aza-BODIPY PSs that inhibit aggregation.
- To evaluate their efficacy for anti-cancer PDT.
Main Methods:
- Synthesis of a novel family of boron-modified aza-BODIPY PSs.
- In vitro assessment of photodynamic efficacy and cytotoxicity.
- In vivo anti-tumor experiments with intravenous administration and irradiation.
Main Results:
- The novel aza-BODIPY PSs demonstrated significantly enhanced in vitro photodynamic efficacy.
- Derivative A1 exhibited a high singlet oxygen yield (rel.rate = 1.79) and potent cytotoxicity (IC50 > 4.5 nM) at a low light dose (21.6 J/cm²).
- In vivo studies showed significant tumor growth suppression with A1, outperforming known PSs like ADPM06 and Ce6.
Conclusions:
- Boron-modified aza-BODIPY PSs effectively inhibit aggregation, enhancing PDT efficacy.
- Derivative A1 is a highly promising near-infrared (NIR) PS for anti-cancer PDT due to its potent efficacy at low drug and light doses.
- This strategy offers a viable approach to overcome PS aggregation challenges in clinical applications.
